Loading
A phase 2 trial of Sirolimus protein-bound particles in metastatic cancer, run by Aadi Bioscience, Inc., active and no longer recruiting.
Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1) is a phase 2 interventional study registered as NCT05103358 by Aadi Bioscience, Inc., with 120 participants planned, started 2022-02-15 and due to reach its primary completion in 2024-12-31. Interventions recorded: nab-sirolimus. Conditions listed: Tumor, Tumor, Solid, Metastasis, Metastatic Cancer. No results are recorded here; the registry entry is the source.
Shares Aadi Bioscience, Sirolimus protein-bound particles, Perivascular epithelioid cell tumour (PEComa), Small-molecule kinase inhibitors.
Shares Aadi Bioscience, Sirolimus protein-bound particles, Small-molecule kinase inhibitors.
Shares Sirolimus protein-bound particles, Perivascular epithelioid cell tumour (PEComa).
Shares Sirolimus protein-bound particles, Perivascular epithelioid cell tumour (PEComa), Small-molecule kinase inhibitors.
Shares Sirolimus protein-bound particles, Perivascular epithelioid cell tumour (PEComa).
Shares Perivascular epithelioid cell tumour (PEComa), Small-molecule kinase inhibitors.